Timofey Glinin retweetledi
BREAKING: Gero Signs Potential Multi-Billion-$ Deal to Fuel Our Mission to Stop Aging --
A few years ago, my son, aged five at the time, asked what happened to the dinosaurs. After learning their sad story, he told me he wanted to fly to the Moon and defend Earth from falling comets. He began assembling his crew—quickly running out of family members and turning to his grandparents—but then stopped and asked: “Dad... Grandpa and Grandma are already old. It will be hard for them to shoot down comets. Can we make it so people don’t age?”
At that tender age, he couldn’t yet fully grasp death, but he already understood aging—and its cruel way of stealing our strength and time. This story has played out billions of times in human history: a child realizes, for the first time, that life is finite. But maybe—just maybe—his generation will be the first to hear a different answer.
Today, we took a step toward that answer. Together with Chugai Pharmaceutical (a member of Roche group), we announced a partnership to develop therapies that target the root causes of major age-related diseases. At Gero, we’ve spent the last 15 years building physics-informed AI models, trained on massive longitudinal datasets tracking human biology over years. These models revealed something critical: in long-lived mammals like humans, aging is mostly an entropic process—slow, irreversible damage that accumulates over time. But diseases? They are failures of individual systems—failures that occur faster in aging bodies but, crucially, are still actionable. Some of these failure points are shared across multiple diseases, and targeting these shared vulnerabilities could lead to therapies that fight multiple diseases at once.
When we started our journey, there were no examples of success to follow. What we had was the belief that science works—and that complex phenomena like aging and chronic diseases could be understood through first principles borrowed from other sciences like physics, and with the help of emerging AI and machine learning tools. We also had no clear idea how to fund such an enterprise. Our inspiration came from nature itself—from mammals like naked mole rats and bats, which show little to no signs of aging over long lifespans.
Things are moving fast. The recent success of GLP-1 drugs (Ozempic, Wegovy) has already shown what’s possible: a single drug class improving metabolic health, heart disease, obesity, and more. What once seemed like science fiction is now reality. And yet, as I argued in my Lifespan's column, these are still just our first flying machines. The real challenge is to build the rockets—to address the fundamental physics of aging, not just its symptoms.
Our models predict three levels of intervention against aging in humans (as always, please do not forget to like, follow and repost before scrolling down for more explanations and links):
1/2
English
